In 2017, European Leukemia Net revised the prognostic model for AML by adding RUNX1 and ASXL1 mutations to the previously identified molecular risk categories, which included mutations in NPM1, CEBPA, FLT3–ITD and TP53. Here, NPM1 is linked to acute myeloid leukemia.